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ABSTRACT: We recently reported the initiation of a Phase I clin-
ical trial with AB680, a potent human CD73 inhibitor, being devel-
oped for the treatment of solid tumors (NCT03677973). We under-
took a detailed kinetic analysis on the interaction between human 
CD73 and AB680 to determine the mode of inhibition. We found 
AB680 to be a reversible, slow-onset competitive inhibitor of hu-
man CD73 with a Ki of 5 pM. Clinical candidates of this potency 
are uncommon and deserve special consideration during lead opti-
mization. 
High concentrations of adenosine in the tumor microenviron-
ment are considered to be immunosuppressive.1 A major source of 
adenosine is the extracellular hydrolysis of adenosine 5ʹ-triphos-
phate (ATP) to adenosine 5ʹ-monophosphate (AMP) and then aden-
osine by the successive actions of ecto-nucleoside triphosphate di-
phosphohydrolase (CD39) and ecto-5ʹ-nucleotidase (CD73). 
Therefore, inhibition of CD73 to reduce extracellular adenosine has 
emerged as a compelling therapeutic target in immuno-oncology.1 
The synthesis of AB680 (Chart 1), an inhibitor of human CD73 
(hCD73) that is being developed for the treatment of solid tumors, 
has recently been reported.2,3 CD73 catalyzes the hydrolysis of 
AMP to adenosine and inorganic phosphate (Pi). AB680 represents 
the culmination of a traditional medicinal chemistry optimization 
campaign initiated by pharmacophore mapping based on the crystal 
structure of hCD73 in complex with alpha, beta-methylene-ADP 
(AOPCP)4 and preliminary structure-activity relationships of N6-
substituted AOPCP derivatives.5 During compound screening and 
the hit-to-lead process, the half-maximal inhibitory concentration 
(IC50) was the primary metric chosen to guide medicinal chemistry 
through multiple synthetic iterations. During the final stages of lead 
optimization that ultimately yielded the clinical candidate 
(AB680), inhibitor IC50 converged rapidly on the enzyme concen-
tration, suggesting potency could be higher than initially thought.  
 
Chart 1. The chemical structure of AB680. 
 
We confirmed tight-binding of AB680 by measuring its IC50 at 
different hCD73 concentrations in the presence of saturating 
amounts of AMP (30 µM) (Figure 1A and B, Figure S3). The IC50 
values decreased linearly with decreasing hCD73 concentration. 
IC50 determinations can vary as a function of enzyme concentration 
as described by eq 1, where Et is total enzyme concentration and 
Kiapp is the mechanism-dependent apparent enzyme-inhibitor disso-
ciation constant.6 Fitting the data with linear regression yielded a 
Kiapp of 13  9 pM across three independent experiments (Figure 
1B, Figure S3). 
 
Figure 1. Tight- and slow-binding of AB680 to hCD73. AB680 
IC50 dependence on (A and B) concentration of hCD73 and (C and 
D) incubation time with hCD73. Data in B were fit by linear regres-
sion, yielding a slope of 0.31. Data in D were fit to eq 3. Panels A 
and B are representative of three independent experiments, whereas 
C and D, represent two. 
 
Steady-state kinetic parameters for the enzyme under our assay 
conditions (Figure S2) were kcat = 46  3 s-1 and a KM = 4.1  0.7 
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µM, resulting in a kcat/KM = (11  2)  106 s-1 M-1. The enzyme 
concentration was determined from an active site titration (Figure 
S1) to ensure the active enzyme concentration was as accurate as 
possible. The enzyme concentration resulting from active site titra-
tion with AB680 was repeatedly close to half the concentration in-
itially obtained from protein absorbance at 280 nm. One way to in-
terpret this observation is that approximately half of the active sites 
are purified in an inactive form. Another, given that hCD73 is a 
dimer, is that AB680 displays half-of-the-sites inhibition, meaning 
one mole of inhibitor is enough to inhibit one mole of the dimer. 
This type of inhibition has been reported, for example, with tight-
binding inhibitors of purine nucleoside phosphorylase.7  
 
IC50 = 0.5  Et + Kiapp       eq 1 
P = (v  t)  (v/kobs)  (1  ekobst)       eq 2 
IC50 = IC50min + (IC50max – IC50min)  t / (t + t1/2) eq 3  
 
We next evaluated whether AB680 binds reversibly to recombi-
nant hCD73. In a jump-dilution experiment, a 200-fold dilution of 
an equimolar mixture of hCD73 and AB680 into AMP leads to a 
slow regain of enzymatic activity, indicating that AMP can eventu-
ally outcompete AB680 for the free enzyme, and that the interac-
tion between enzyme and inhibitor is reversible (Figure 2, Figure 
S4). There was an initial lag before enzymatic activity was recov-
ered, highlighting the slow dissociation of AB680 from hCD73. 
Fitting the data to eq 2, where P is inorganic phosphate (Pi) concen-
tration, t is time post-dilution, v is the steady-state rate and kobs is 
the observed first-order rate constant for dissociation of the EI com-
plex, yielded kobs of (2.48  0.03)  10-4 s-1.  
 
 
 
Figure 2. Regain of activity of hCD73. Data were best fit to a 
straight line (circles) and to eq 2 (squares). The data are representa-
tive of two independent experiments. 
It is common for inhibitors in this affinity range to display time-
dependent inhibition.8,9 Accordingly, pre-incubation of hCD73 
with AB680 revealed that IC50s were time-dependent, with increas-
ing pre-incubation times resulting in decreasing IC50 values until a 
plateau is reached around 30 min (Figure 1C and D, Figure S5). 
This suggests that AB680 does not establish an overall rapid equi-
librium with hCD73, but instead binds slowly to the enzyme. The 
slow-onset inhibition of hCD73 by AB680 is in line with reports 
for other non-covalent tight-binding inhibitors such as immucillin-
H, which inhibits purine nucleoside phosphorylase,7 and pentacy-
ano(isoniazid)ferrate(II), which inhibits 2-trans-enoyl-ACP reduc-
tase.10  
Three possible kinetic mechanisms have been invoked to explain 
slow-onset, non-covalent reversible enzyme inhibition (Scheme 
S1).8 The inhibitor may bind to the enzyme in a single, slow step 
(Scheme S1A), or in two steps, a rapid equilibrium binding fol-
lowed by a slow conformational change of the enzyme-inhibitor 
complex (Scheme S1B). A third possibility includes a slow confor-
mational change of the free enzyme, followed by fast inhibitor 
binding (Scheme S1C).  
To distinguish among these three mechanisms, progress curves 
were determined for the hCD73 reaction at several concentrations 
of AB680 and analyzed by numerical integration using KinTek Ex-
plorer11 (Figure 3A). Data fitting in KinTek Explorer was at-
tempted for all three mechanisms, but only the mechanism reflect-
ing Scheme S1A converged on a solution. The following parame-
ters were used to generate the fit: k1, describing substrate binding 
to the enzyme, was constrained within an acceptable range for dif-
fusion-limited binding (100 – 1000 µM-1 s-1), k-1, the unimolecular 
dissociation rate constant for the enzyme-substrate complex, was 
set to k1KM, which assumes a simple rapid equilibrium between E 
and ES, and k-2 was set to 0, since the hydrolytic reaction is irre-
versible. The remaining parameters were allowed to fluctuate un-
constrained during the simulation. This process yielded k3 = 73  
20 M-1 s-1, the bimolecular rate constant for inhibitor binding to 
the enzyme, and k-3 = (4  2)  10-4  s-1, the unimolecular dissocia-
tion rate constant for the enzyme-inhibitor complex, which results 
in Ki = 5  3 pM. A k2 = 49  1 s-1, the steady-state catalytic con-
stant, was also obtained. Errors reported are the boundaries result-
ing from FitSpace. The values are remarkably consistent when 
compared with those obtained from other experiments, with k2 in 
close agreement to kcat (46 s-1), lending support to the assumption 
of rapid equilibrium (k2 << k-1), k-3 in close agreement to kobs (2.48 
 10-4 s-1) from the jump-dilution experiment, and Ki in range of 
Kiapp (13 pM). This lends further support to the proposed inhibition 
mechanism. Furthermore, multidimensional parameter analysis us-
ing FitSpace12 showed the values are well-constrained by the model 
(Figure 3B-D). This is true only for the model comprising a single 
binding step between inhibitor and enzyme.      
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Figure 3. Numerical integration of hCD73 reaction progress curves in the presence and absence of AB680. (A) Data conversion to a single-
step binding mechanism between enzyme and inhibitor. (B-D) FitSpace analysis of the resulting parameters, where the red space delineates 
the range of values within which the parameters can fluctuate as a function of one another and still be constrained by the model.   
  AB680 is an extraordinarily potent, slow-onset, reversible, 
competitive inhibitor of hCD73. Unlike pentacyano(isoniazid)fer-
rate(II) which inhibits its target with a two-step binding mecha-
nism13, AB680 appears to bind hCD73 in a single slow step. This 
is a similar binding mode to Immucillin-H, which was originally 
proposed to inhibit its target with a two-step binding mechanism7, 
but upon reanalysis with numerical integration was found to bind 
in a single slow step.11 It should be noted that reports of one-step-
binding slow-onset inhibitors are relatively rare in comparison with 
those of two-step binding. The inhibition of extracellular signal-
regulated kinase14 and of p3815 showcase recent examples of one-
step-binding slow-onset inhibition. Additionally, specific kinetic 
factors might lead to the mechanism in Scheme S1B presenting it-
self as that of Scheme S1A. If the Ki for the first step of the two-
step binding mechanism is several orders of magnitude larger Ki* 
(reflecting the higher affinity for the inhibitor after isomerization 
of the EI complex), the concentration of the EI complex will be 
negligible in comparison to that of EI*, and the mechanism will 
resemble one-step binding in progress curves.9 Likewise, the initial 
bimolecular formation and unimolecular dissociation of the EI 
complex may be too fast to capture by manual-mixing inhibition 
progress curve analysis.11 Therefore, while numerical integration 
of the progress curves presented here along with internal con-
sistency with other experiments support one-step binding of AB680 
to hCD73, a two-step binding mechanism cannot be entirely ruled 
out, and future structural and molecular dynamics data, along with 
pre-steady-state kinetics, may be needed to unequivocally ascertain 
the mechanism.  
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Compounds as potent as AB680 illustrate the need to recognize 
limitations and adapt quantitative approaches accordingly. This be-
comes necessary to discover precise kinetic parameters as leads be-
come more potent and inhibitor concentration approaches the en-
zyme concentration. Since the Ki of AB680 is likely well-below the 
concentration of hCD73 in vivo, the physiological potency of the 
drug will be a function of enzyme concentration in the treated tis-
sue, which will have direct implication for dosage.  
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